Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 160 mg Monotherapy

NCT01001572 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01001572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01001572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-national, Multi-center, Double-blind, Randomized, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 160/5 mg to Valsartan 160 mg Alone in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 160 mg Monotherapy
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
May 31, 2010
Enrollment
932 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension